Robert Thomas Dechant, Chief Executive Officer and Director of IBEX Ltd, filed a Form 4 on November 3, 2026, disclosing the acquisition of 37,500 restricted stock units on October 30, 2026, at a price of $0.

Key Highlights

  • Reporting person: Robert Thomas Dechant, serving as both Director and Chief Executive Officer of IBEX Ltd (NASDAQ:IBEX).
  • Transaction: 37,500 restricted stock units (RSUs) acquired on October 30, 2026, via transaction code A, at a price of $0.
  • Vesting schedule: 25% of the granted RSUs vest annually over four years, commencing September 30, 2027, subject to continuous service on each vesting date.
  • Post-transaction ownership: Following the grant, Dechant beneficially owns 302,448 common shares directly.
  • Tax withholding: On each vesting date, the issuer will automatically withhold shares to satisfy the reporting person's tax withholding obligations in a non-discretionary transaction.
  • Filing signed: Lisa Lenstrohm, Attorney-in-Fact, signed the form on November 3, 2026.

IBEX CEO Granted RSUs With Four-Year Vesting Starting 2027

According to the Form 4 filed with the SEC on November 3, 2026, Robert Thomas Dechant, the Chief Executive Officer and a Director of IBEX Ltd (NASDAQ:IBEX), was granted 37,500 restricted stock units on October 30, 2026. The filing records the transaction under code "A" (acquired) in Table I - Non-Derivative Securities, with a reported price of $0. Each RSU represents a contingent right to receive one share of the issuer's common stock.

As described in the filing's explanation of responses, the RSUs vest at a rate of 25% per year over four years, with the first vesting date set for September 30, 2027. Vesting is conditioned on the reporting person remaining in continuous service on each applicable vesting date. The filing further states that, unless otherwise provided, the issuer will automatically withhold shares on each vesting date to cover the reporting person's tax withholding obligations, characterizing this as a non-discretionary transaction.

Following the reported grant, Dechant's direct beneficial ownership of IBEX Ltd common shares stands at 302,448, as disclosed in Table I of the filing. No derivative securities transactions were reported in Table II. The form was filed by one reporting person and was signed by Lisa Lenstrohm as Attorney-in-Fact.

What Was Disclosed

The filing disclosed the grant of 37,500 RSUs to IBEX Ltd's CEO Robert Thomas Dechant on October 30, 2026, at $0, with annual vesting of 25% beginning September 30, 2027, bringing his direct beneficial ownership to 302,448 common shares.